Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
The Journal of Clinical Investigation|October 20, 2007
Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voidingThomas Gevaert, Joris Vriens, Andrei Segal, et al.
Expert Review of Anticancer Therapy|November 23, 2020
Current and emerging therapies for localized high-risk prostate cancerLisa Moris, Gaëtan Devos, Thomas Van den Broeck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 13, 2024
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancerNiloefar Ahmadi Bidakhvidi, Thomas Gevaert, Maxim De Schepper, et al.
European Urology Open Science|July 24, 2024
Fibroblast Activation Protein-α and the Immune Landscape: Unraveling T1 Non-muscle-invasive Bladder Cancer ProgressionTim Muilwijk, Loïc Baekelandt, Murat Akand, et al.
The Journal of Urology|November 14, 2019
Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node DissectionCédric Draulans, Wouter Everaerts, Sofie Isebaert, et al.
BMC Cancer|April 3, 2018
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trialLorenzo Tosco, Annouschka Laenen, Thomas Gevaert, et al.
Oncotarget|March 26, 2016
Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1Lien Spans, Thomas Van den Broeck, Elien Smeets, et al.
ESMO Open|August 11, 2018
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancerChristian Rolfo, Paolo Manca, Roberto Salgado, et al.
European Urology|September 27, 2022
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate CancerGaëtan Devos, Lorenzo Tosco, Marcella Baldewijns, et al.
Molecular Cancer Research : MCR|January 27, 2022
Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate CancerThomas Van den Broeck, Lisa Moris, Thomas Gevaert, et al.
Pageof 7